Restenosis occurs in 35% of patients within months after balloon angioplasty, due to a fibroproliferative response to vascular injury. These studies describe a combined fibrosuppressive/antiproliferative strategy on smooth muscle cells cultured from human primary atherosclerotic and restenotic coronary arteries and from normal rat aortas. LMimosine suppressed the posttranslational hydroxylation of the precursors for collagen and for eukaryotic initiation factor-5A (eIF-5A) by directly inhibiting the specific protein hydroxylases involved, prolyl 4-hydroxylase (E.C. 1.14.11.2) and deoxyhypusyl hydroxylase (E.C. 1.14.99.29), respectively. Inhibition of deoxyhypusyl hydroxylation correlated with a dose-dependent inhibition of DNA synthesis. Inhibition of prolyl hydroxylation caused a dose-dependent reduction in the secretion of hydroxyproline-containing protein and decreased the formation of procollagen types I and III. The antifibroproliferative action could not be attributed to nonspecific or toxic effects of mimosine, appeared to be selective for the hydroxylation step in the biosynthesis of the procollagens and of eIF-5A, and was reversible upon removal of the compound. The strategy of targeting these two protein hydroxylases has important implications for the pathophysiology of restenosis and for the development of agents to control fibroproliferative diseases.
Introduction
Cell proliferation and matrix production are important elements of any tissue's response to injury. Both processes are essential in physiological wound repair, but, in excess, they contribute Volume 95, February 1995, 446-455 to pathological conditions that can compromise organ function. One of the most destructive clinical manifestations of excessive wound healing occurs at focal sites in the vasculature. Atherosclerotic lesions, with their associated mineralization and lipid accumulation, lead to ischemic, rheological, and prothrombotic complications in coronary, carotid, and peripheral arteries (1) . Although angioplasty can achieve initial reperfusion in 95% of atherosclerotic occlusions, progressive fibroproliferative reocclusion occurs within 6 mo postoperatively in at least 35% of the more than 300,000 patients in the United States alone (2) . Despite promising results in animal models, restenosis in humans has been resistant to a variety of medical interventions (for review see reference 2).
The predominant proliferative component of the restenotic lesion is a large dendritic cell expressing the contractile a-actin isoform (3), a marker for both smooth muscle cells (SMC)' and myofibroblasts (4) . SMC derived from restenotic lesions proliferate more rapidly than cells from primary atherosclerotic lesions (5, 6) . In experimental models of arterial injury, SMC show a proliferative peak 4-7 d after injury followed by elevated proliferation for weeks after injury (7, 8) . SMC at the injury site rapidly increase gene expression of profibrotic cytokines such as transforming growth factor-,31 (TGF-/31), followed by markedly enhanced expression of collagen type I and III component a chains (9) . SMC derived from restenotic lesions produce two-to threefold higher levels of collagen and proteoglycans than SMC derived from umbilical arteries (10) . Collagens are known to act as a scaffold for proteoglycans and glycoproteins (11, 12) and, thus, form a depository for TGF-/31 (13) (14) (15) , PDGF (16) , and the fibroblast growth factors (17) . These matrix-bound mediators could provide an ongoing signal for proliferation, matrix production, and augmented growth factor expression ( 18) . In this way, the de novo synthesis of collagens could create an intralesional nidus of profibrotic growth factors which sustain the fibroproliferative response.
We noted that both cell proliferation and extracellular matrix formation depend on the hydroxylation of specific proteins, the eukaryotic initiation factor-5A (eIF-5A) and the collagens, respectively. In eIF-5A, this unique hydroxylated amino acid residue is hypusine [NE-(4-amino-2(R)-hydroxybutyl)lysine].
The synthesis of functional eIF-5A involves two distinct posttranslational modifications: (a) the NAD+-dependent transfer of a spermidine-derived 4-aminobutyl moiety onto the E-amino 1. Abbreviations used in this paper: eIF-5A, eukaryotic initiation factor-SA; IC50, half-maximal inhibitory concentration; LDH, lactate dehydrogenase; PAI-1, plasminogen activator inhibitor-1; PIIINP, NH2-terminal group of a single sequence-defined lysine residue, generating deoxyhypusine (19) ; and (b) the stereospecific hydroxylation of its carbon 9 by the metalloenzyme deoxyhypusyl hydroxylase (E.C. 1.14.99.29), generating hypusine (20) . Hypusine has been identified only in eIF-5A (21, 22) . Inhibition of deoxyhypusyl hydroxylase correlates with reversible arrest of cell proliferation, causing the accumulation of cells in the late GI phase of the cell cycle, apparently by interfering with the onset of DNA replication (21, 23) .
In collagens, the crucial hydroxylated residues are trans 4-hydroxyprolines, formed posttranslationally by prolyl 4-hydroxylase (E.C. 1.14.11.2). This enzyme, an aZ62-tetrameric, divalent iron-containing dioxygenase, stoichiometrically uses 2-oxoglutarate and molecular oxygen for the hydroxylation of a sequence-defined proline residue. The mechanism of prolyl 4-hydroxylase proposed by Hanauske-Abel and Gunzler (24) has been used successfully to guide the design of prolyl 4-hydroxylase inhibitors (25, 26) . Suppression of prolyl hydroxylation prevents the formation of the collagenous triple helix which is required for the secretion of at least the interstitial procollagens. In this way, inhibition of prolyl 4-hydroxylase selectively reduces formation of the extracellular matrix (25) .
The active sites of deoxyhypusyl hydroxylase and prolyl 4-hydroxylase have been probed with reporter molecules (27, 28) . Both protein hydroxylases recognize -Gly-x-y-Gly-motifs in their respective substrates and both.of their active sites contain (a) a tightly bound metal ion accessible to low molecular weight ligands; and (b) an ionic side chain for salt-bridging ligands. Certain catecholpeptides which mimic the -Gly-x-yGly-motif and inhibit purified prolyl 4-hydroxylase also suppress deoxyhypusyl hydroxylase in vitro (27) . Nonpeptide compounds like 3,4-dihydroxybenzoic acid (3,4-DHBA) also inhibit both protein hydroxylases (27, 29) . The catecholpeptides and 3,4-DHBA are, however, not stable under biological conditions due to the redox reactivity of their aromatic dihydroxybenzene moiety (30) . Thus, L-mimosine, a naturally occurring catechol analogue with a biologically stable, nonaromatic 3-hydroxypyridin-4 one ring, was selected as a pilot compound (Fig. 1) .
These studies provide the first evidence that mimosine, but not its ring isomer kojic acid, acts as an inhibitor for both protein hydroxylases in cultured vascular cells. (4 p/Ci/ml) for 24 h in proline-and serum-free DME containing 50 ,g/ml sodium ascorbate and 20 tig/ml /3-aminopropionitrile, as described previously (32) . The supernatants were precipitated in 10% TCA, hydrolyzed (6 N HCl, 1 10C, 16 34) , using an automated HPLC system (Hewlett-Packard Co., Wilmington, DE) with an in-line scintillation counter (Inus Systems, Inc., Tampa, FL). All concentrations were tested in replicates of three wells.
Assays of purified human prolyl 4-hydroxylase. The native a2/32-tetrameric enzyme was purified to homogeneity by poly(L-proline) affinity chromatography and DEAE chromatography from the supernatant of Spodoptera frugiperda insect cells cotransfected with recombinant baculovirus transfer vectors for both the human a-and /-subunits (35) . Enzyme activity was determined by trapping of "'CO2 released from 2-oxo [1-"'C] glutarate as described (28) . Briefly, all incubations were run for 60 min at 370C in a final volume of 1.0 ml per test sample, containing 0.1 t'g enzyme, 0.1 mg heat-denatured (Pro-Pro-Gly),0 x 9 H20 as hydroxylatable substrate, 0. (30-40%) of cells spontaneously showed strong reactivity toward the antia-actin antibody (Fig. 2, lower right) , and essentially all cells became a-actin-positive upon serum withdrawal and treatment with TGF-,31 (< 1 ng/ml), a characteristic of both SMC (39) and myofibroblasts (4, 
40).
Effect of mimosine and kojic acid on cellular deoxyhypusyl hydroxylase activity. The inhibition of deoxyhypusyl hydroxylase has been shown to correlate with proliferative arrest at the G1-S boundary (23) . When the enzyme was studied in vitro, mimosine caused almost complete inhibition at 50 MM, whereas even 300 MM of kojic acid was not inhibitory (23) . Deoxyhypusyl hydroxylase activity in SMC also was not suppressed by kojic acid (data not shown), but mimosine had a marked inhibitory effect. In atherectomy-derived human SMC and in normal rat aortic SMC, mimosine caused a dose-dependent decrease of the enzyme's hydroxylated product, hypusine, and a concomitant increase in the unhydroxylated intermediate (Fig. 3, inset) . Dose-response analysis in rat SMC confirmed that maximal inhibition of cellular deoxyhypusyl hydroxylase activity is achieved at 400 ,M mimosine, with an apparent half-maximal inhibitory concentration (IC50) of 160 MM (Fig. 3) . Total ['H] spermidine incorporation was unaffected in the 100-200 MM range and was reduced at 400 MM by just 11%. These findings suggest that significant disruption by mimosine of the metabolic steps before hydroxylation of the eIF-5A precursor did not occur. Apparently, the biosynthetic flow through the hypusination pathway, with its key elements of polyamine transport, protein precursor formation, and butylamine transfer, continues unaffected at concentrations of mimosine that completely suppress its final step, deoxyhypusyl hydroxylation.
The effect ofmimosine and kojic acid on vascular cellproliferation. Mimosine was a potent inhibitor of DNA synthesis in SMC derived from primary atherosclerotic lesions, with an apparent IC50 of -90 JIM (Fig. 4, top) . Two ,sM (Fig. 4, bottom) . In cells from both species, inhibition of proliferation was essentially complete at 400 AM mimosine, (Fig. 4,  bottom) . After the initial 24-h incubation, DNA synthesis was inhibited by mimosine, but not by kojic acid. Upon drug removal and an additional 24-h recovery period, there was a marked rebound DNA synthesis in the mimosine-arrested, but not in the kojic acid-treated cells. This finding is consistent with synchronous release of a large cohort of SMC from a mimosine-sensitive arrest point just before initiation of DNA replication, an effect previously demonstrated by flow cytometry in other cell types (23) . Cell cycle analysis using acridine orange-stained rat SMC confirmed that mimosine induced a reversible accumulation of cells at the Gl-S boundary (not shown).
Effect of mimosine and kojic acid on purified human prolyl 4-hydroxylase. The structural similarities between mimosine and 3,4-dihydroxybenzoic acid (Fig. 1) , a known prolyl-4-hydroxylase inhibitor, suggested that mimosine and kojic acid might be effective inhibitors. Thus, the interaction of mimosine and kojic acid with the purified human enzyme was investigated. As the active site metal ion is reversibly lost under nonturnover conditions, the enzyme becomes metal-depleted during purification and needs to be restored in vitro by the addition of ferrous ions (41 (Fig. 6) . These results indicate that mimosine quite specifically inhibits prolyl hydroxylation, with minimal, if any, consequence for the overall synthesis of cellular proteins. In culture, such a preferential effect has been observed before only with agents that directly interact with prolyl 4-hydroxylase, whereas a metal chelator, like 2,2 '-dipyridyl, diminishes hydroxyprolyl generation and total protein biosynthesis to the same degree (32) . In contrast, kojic acid caused only a 30% reduction in hydroxyproline formation at 500 ILM and, thus, was less effective than mimosine. The suppression of cellular prolyl hydroxylase activity by mimosine was rapidly reversible upon removal of the inhibitor. Rat SMC treated with mimosine (500 [SM) for 24 h showed hydroxyproline/proline ratios reduced to < 60% of control levels (P < 0.01), which significantly increased to 90% of control levels 24 h after drug withdrawal (P < 0.05). Effect of mimosine on the secretion of type I and III procollagens in human vascular SMC. Type I and III procollagens are the most prominent collagenous proteins synthesized by vascular SMC in their synthetic state, which predom- Mimosine [1xMJ Figure 6 . Inhibition of prolyl hydroxylation in human coronary and rat aortic SMC by mimosine. SMC derived from a human coronary restenotic lesion (shown in Fig. 2 inates after passaging in culture and is thought to be representative of cells in vascular lesions (44) . Type III procollagen expression increases as a reaction to injury of the rat aorta in vivo (9) . In humans, the serum levels of PIIINP are known to indicate fibrotic changes in the coronary arteries (45) . PIIINP is cleaved extracellularly by a specific N-proteinase before fibril formation, and, thus, is a stoichiometric marker for matrix deposition of type III collagen. Consistent with its ability to suppress prolyl hydroxylation, mimosine reduced PIIINP secretion to -50% of control levels (Fig. 7) . In contrast, the production of PAI-1, a noncollagenous protein, was not affected even at the highest inhibitor concentrations. Thus, it is unlikely that mimosine causes a nonspecific reduction of protein export in general, but, rather, this compound appears to decrease the secretion of proteins which, like the interstitial procollagens, display a triple helical and therefore hydroxyproline-dependent domain. Such a discriminating effect was observed previously with specific prolyl 4-hydroxylase inhibitors like the pyridine dicarboxylates (32) . In vivo, type I collagen is also expressed by SMC in response to vascular injury (9). In the current study, the secretion of procollagen type I was examined by Western blot analysis using a polyclonal antibody directed against the globular, trimeric C-propeptide C3 which is proteolytically cleaved by a specific C-proteinase from the hydroxyproline-containing triple helix in a 1:1 ratio upon secretion (36) . The formation in the supernatant of the 72-kD C3 antigen was markedly decreased by mimosine over a 24-h period (Fig. 8) . Densitometric analysis of triplicate immunoblots indicated a reduction of C3 to -50% at the highest concentration of mimosine.
The immunological techniques used for measuring C3 and PIIINP exhibited less marked decreases in response Miiosine [RM] Figure 7 . Secretion of PIIINP and PAI-I activity from human coronary SMC. SMC derived from a restenotic coronary plaque were treated under serum-free conditions for 24 h with the specified doses of mimosine followed by PIIINP RIA (left axis, closed symbols). Data are expressed in milliUnits per milliliter of supernatant (mean+SEM, n = 3).
PAI-l was assayed by fluorometric assay for the inhibition of plasmin generated from urokinase and plasminogen (right axis, open symbols). ond, the antibodies cannot discriminate propeptides formed rapidly during secretion from propeptides slowly released from the matrix. Toxicity ofmimosine and kojic acid. In the time frame tested, no sign of toxicity of mimosine on SMC was observed. In addition to the reversibility of the inhibitory effects on proliferation and collagen hydroxylation, the cells remained viable and biosynthetically active as demonstrated by (a) the number of trypan blue-excluding cells (Table I) ; (b) the absence of detectable leakage of cytoplasmic LDH (Table I) ; and (c) the continued synthetic capacities, as reflected by the metabolic labeling of new protein with [3H] proline (Fig. 6 ) and of precursor eIF-5A with [3H] spermidine (Fig. 3 ) , and by the unaffected secretion of PAI-1 activity (Fig. 7) .
Discussion
The vascular response to injury, in the form of cell migration, cell proliferation, and extracellular matrix accumulation, is driven by numerous growth factors and cytokines (1) . Because of this inherent mediator redundancy, intentional interruption of the response to an individual mediator may be insufficient to alter the overall tissue reaction. The present strategy targets the pivotal posttranslational hydroxylation of proteins required in the common pathway of both cell proliferation and collagen synthesis, irrespective of which growth factors and cytokines drive these responses. The antifibroproliferative effect of a protein hydroxylase inhibitor, like mimosine, is unconstrained by the biological complexity of the mediator network underlying fibroproliferative diseases.
The intentional interference with specific posttranslational modifications is a widely accepted principle of medical therapeutics and a routine event in clinical practice. The Figure 9 . Proposal for the antifibroproliferative effect of a protein hydroxylase inhibitor such as mimosine. The diagram emphasizes the similarity in active site organization between prolyl 4-hydroxylase and deoxyhypusyl hydroxylase with regard to their respective peptide substrate, which in each case displays a -Gly-x-y-Gly motif (glycine residues highlighted in gray), and its relation to the active site metal (Me) which is thought to generate and orient a reactive oxygen atom species (0) for stereospecific attack on the prolyl C4 and the deoxyhypusyl C9 atoms, in this way mediating hydroxylation (arrows) (24, 25, 27) . Apparently, mimosine is able to access the tightly bound metal ion (Me) and to block its role in catalysis. Inhibition of prolyl 4-hydroxylase directly suppresses the hydroxyproline-dependent formation and secretion of triple helical collagens (25) ; inhibition of deoxyhypusyl hydroxylase compromises cell proliferation, by a mechanism not yet completely understood in molecular detail (23) . summarized in Fig. 9 . The function suppressed in each biosynthetic pathway is the posttranslational formation of the hydroxylated, peptide-bound amino acid residues trans 4-hydroxyproline and hypusine, which are required for the biological activity of these proteins. In the absence of physiologically structured collagens and eIF-5A, connective tissue formation and cell proliferation both come to a halt independently and both resume rapidly upon removal of the inhibitor. The reversibility of these effects implies that, in vivo, the inhibitor will need to be present until the mitogenic and profibrotic stimuli have subsided.
The present results indicate that a single inhibitor of protein hydroxylation is able to suppress both collagen secretion and cell proliferation in cultured vascular cells of the human coronary arteries and the rat aorta. Mimosine directly inhibits prolyl 4-hydroxylase (Fig. 5 ) and deoxyhypusyl hydroxylase (23) , which in cells blocks the secretion of de novo synthesized collagens (25) and inhibits cell proliferation (23) (Figs. 4 and 6) . Inhibition of prolyl 4-hydroxylation leads to intracisternal misfolding of only the collagenous proteins, resulting in a dosedependent reduction of their secretion (32, 46) . Apparently, mimosine selectively inhibits hydroxylase activity, which resides in the a subunits of prolyl 4-hydroxylase (47), but does not compromise the role of its / subunits in the intracellular retention of misfolded procollagens (48) .
The simultaneous suppression of both protein hydroxylases by a single agent implies that, in addition to the similarities in their peptide binding sites, the active sites of prolyl 4-hydroxylase and deoxyhypusyl hydroxylase are structured alike. Indeed, the three-dimensional models proposed for the architecture of each enzyme's active site (24, 25, 27) show common structural elements which outline the structure-activity relation for the dual action of mimosine.
In both enzymes, the protein-bound metal atom at the active site, proposed to mediate the hydroxylation by transfer of an oxygen atom (Fig. 9) , provides coordination sites for a bidentate ligand. The active sites are thought to also display a polar amino acid side chain able to form a stabilizing salt bridge with an appropriately charged ligand, requiring a negative charge in case of prolyl 4-hydroxylase and a positive charge in case of deoxyhypusyl hydroxylase (24, 25, 27) . We propose that these structural prerequisites for interaction with either enzyme are met by the amino acid moiety of mimosine. Its ionic interaction positions the 3-hydroxy-4-keto moiety to chelate the active site metal of each protein hydroxylase. This hypothesis accounts for the fact that mimosine-like molecules require a carboxyl moiety to inhibit procollagen formation (29, 49) , whereas they require an amino group to inhibit proliferation (50). These distinctions may be useful for the further development of compounds that selectively target only one protein hydroxylase. Indeed, the potent prolyl 4-hydroxylase antagonists pyridine 2,4-dicarboxylate and pyridine 2,5-dicarboxylate (28) lack the ability to inhibit deoxyhypusyl hydroxylase (20) and they do not affect cell proliferation or cell cycle transit (McCaffrey, T. A., and H. M. Hanauske-Abel, unpublished observation).
The prerequisite for interaction with both the charged side chains and the metal ion appears to be quite stringent for prolyl 4-hydroxylase and for deoxyhypusyl hydroxylase, as evidenced by the findings obtained with kojic acid. This agent, which cannot bind to the charged side chain at the active site of either enzyme, but whose ring is bioisosteric to the one in mimosine (Fig. 1) and like mimosine interacts with metal, was not inhibitory for deoxyhypusyl hydroxylase (23) and only weakly inhibitory for prolyl 4-hydroxylase (Fig. 5) . Therefore, the ability to bind metal is, by itself, not sufficient to effectively access the active site of either prolyl 4-hydroxylase or deoxyhypusyl hydroxylase and inhibit enzyme activity. Generalized metal chelation by an agent like desferrioxamine can, however, reduce vascular SMC proliferation in vitro and in vivo (51 ) .
After oral administration in animals, plasma levels of mimosine could be maintained in the range of concentrations that were biologically active in the present studies (100-300 IsM) (52) . However, because both protein hydroxylases have important functions in normal tissue, ideally their use would be restricted to the site of the fibroproliferative response. Fortunately, drugs, or bioactivatable prodrugs, could be applied locally either by a perfusion catheter (53) or by resorbable vascular stents acting as a depot for the slow release of agent into the local environment (54) . Intramural application of these agents would also place the inhibitor beneath the intimal surface and would thus minimize the antiproliferative effect on reendothelialization, which occurs both by migration and proliferation (55) . Thus, the antifibroproliferative action of protein hydroxylase inhibitors could be targeted to specific vascular regions to interfere with the establishment of an intralesional collagenous nidus of factors that sustain the fibroproliferative response. Protein hydroxylase inhibitors, like mimosine, will be useful tools for determining the impact of cell proliferation and collagen synthesis in vascular restenosis and other fibroproliferative disorders.
